BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
This specialized system features cholesterol-polyethylene glycol-glycyrrhetinic acid modified liposomes (Chol-PEG-GA PLs) configured as an affinity-coupled target modeling matrix. The vesicle architecture utilizes a stable phospholipid bilayer shell whose exterior boundary is covalently functionalized with a dense layer of pentacyclic triterpenoid glycyrrhetinic acid (GA) targeting ligands linked via cholesterol-polyethylene glycol (Chol-PEG) polymer-lipid anchors. This surface modification alters the surface charge topography, membrane elasticity, and introduces a dense hydrophilic shield that prevents physical vesicle aggregation in open suspension. The resulting vesicles exhibit high colloidal stability and a highly uniform spherical morphology.
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.